{
    "2021-11-23": [
        [
            {
                "time": "2021-03-15",
                "original_text": "COVID-19 vaccines have ‘proved their merit at this point’: Doctor",
                "features": {
                    "keywords": [
                        "COVID-19",
                        "vaccines",
                        "proved",
                        "merit"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-04-20",
                "original_text": "Top Analyst Reports for Johnson & Johnson, Netflix & Oracle",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Netflix",
                        "Oracle",
                        "analyst reports"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "technology",
                        "entertainment"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-05-05",
                "original_text": "Countries pushing vaccine IP waivers ‘want to take advantage of the technology’: Fmr. U.S. Commerce Secretary",
                "features": {
                    "keywords": [
                        "vaccine",
                        "IP waivers",
                        "technology",
                        "Commerce Secretary"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "government"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-07-18",
                "original_text": "COVID-19: The U.S. issues advisory for travel to Europe but has no plans for a lockdown",
                "features": {
                    "keywords": [
                        "COVID-19",
                        "U.S.",
                        "advisory",
                        "travel",
                        "Europe",
                        "lockdown"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "travel",
                        "government"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-11-10",
                "original_text": "Will Investors Benefit From Johnson & Johnson's Breakup?",
                "features": {
                    "keywords": [
                        "Investors",
                        "Johnson & Johnson",
                        "Breakup"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-05",
                "original_text": "4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout",
                "features": {
                    "keywords": [
                        "Arrowhead Pharmaceuticals",
                        "Biotech",
                        "Buyout"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}